1. Home
  2. Erlotinib
  Subject:

Erlotinib   New Search

View on DBpedia    View on Wikipedia
Top related subjects:
 Growth factor Estrogen receptor Tyrosine-kinase inhibitor Non-small-cell lung carcinoma Chemotherapy Tyrosine kinase Enzyme inhibitor Apoptosis Western blot Targeted therapy Erlotinib Protein Gene Messenger RNA Breast cancer Hormone Neu! Sunitinib Receptor tyrosine kinase Carcinoma Adenocarcinoma Radiation therapy Neoadjuvant therapy Metastasis Bcl-2 Flow cytometry
RELATED SUBJECTS:
The publications listed also have these subjects
Growth factor  8 times
Estrogen receptor  8 times
Tyrosine-kinase inhibitor  6 times
Non-small-cell lung carcinoma  6 times
Chemotherapy  4 times
Tyrosine kinase  3 times
Enzyme inhibitor  3 times
Apoptosis  3 times
Western blot  2 times
Targeted therapy  2 times
Progression-free survival  2 times
Phosphoinositide 3-kinase  2 times
Oncology  2 times
Neu!  2 times
Monoclonal antibody  2 times
Genome  2 times
Gefitinib  2 times
Cell cycle  2 times
Carcinoma  2 times
Ukraine  1 time
Tyrosine  1 time
Triple-negative breast cancer  1 time
Time  1 time
TNBC  1 time
Systems biology  1 time
Sunitinib  1 time
Standard deviation  1 time
Small-cell carcinoma  1 time
Small interfering RNA  1 time
Scopus  1 time
Salvage therapy  1 time
Receptor tyrosine kinase  1 time
Pulmonary alveolus  1 time
PubMed  1 time
Prednisolone  1 time
Placenta  1 time
Phosphate  1 time
Pharmacokinetics  1 time
Peru  1 time
Performance status  1 time
PH  1 time
Oncolytic virus  1 time
Non-player character  1 time
Nicotine  1 time
Necrosis  1 time
Multivariate analysis  1 time
Mitsubishi Ki-67  1 time
Methotrexate  1 time
Methanol  1 time
Metastasis  1 time
Metabolite  1 time
Metabolism  1 time
Metabolic pathway  1 time
Medicaid  1 time
Mass spectrometry  1 time
Lung cancer  1 time
List of breast cancer cell lines  1 time
Library  1 time
KRAS  1 time
Interstitial lung disease  1 time
India  1 time
Immunofluorescence  1 time
Imatinib  1 time
Green tea  1 time
Google Scholar  1 time
Glucose  1 time
Glioma  1 time
Glioblastoma multiforme  1 time
Gene therapy  1 time
Gene  1 time
Gemcitabine  1 time
Gas chromatography  1 time
Gallocatechol  1 time
Gallic acid  1 time
Fuel injection  1 time
Fatty acid  1 time
Epigallocatechin gallate  1 time
Cyclin  1 time
Cuba  1 time
Crizotinib  1 time
Cotinine  1 time
Confidence interval  1 time
Colombia  1 time
Cochrane Library  1 time
Classical mechanics  1 time
Chromatin  1 time
Chitosan  1 time
China  1 time
Central nervous system  1 time
Caspase 3  1 time
Carbon  1 time
Capecitabine  1 time
Bone marrow  1 time
Bevacizumab  1 time
Bcl-2-associated X protein  1 time
Autophagy  1 time
Argentina  1 time
Aptamer  1 time
Annexin  1 time
Androgen receptor  1 time
Androgen  1 time
Adjuvant  1 time
Adenocarcinoma  1 time

Publications tagged with this subject: 15

Note: Top 50 publications shown only. Open an item panel to view more info (open all)


1. Simultaneous Determination of Erlotinib and its Metabolites in Human Urine and Serum Samples by High-Performance Liquid Chromatography

2. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities

3. Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP)

4. Impact of pharmacy channel on adherence to oral oncolytics

5. The 150 most important questions in cancer research and clinical oncology series: questions 50–56

6. Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab

7. Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer

8. Aptamer-Conjugated Chitosan-Anchored Liposomal Complexes for Targeted Delivery of Erlotinib to EGFR-Mutated Lung Cancer Cells

9. In vitro evaluation of combination of EGCG and Erlotinib with classical chemotherapeutics on JAR cells

10. Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro

11. Cost-effectiveness of lung cancer screening and treatment methods: a systematic review of systematic reviews

12. Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

13. A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent

14. EGFR-targeted therapies in the post-genomic era

15. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease


Questions?

Drop us a message.